Enanta Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Enanta Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count).
Enanta Pharmaceuticals: 36 sponsored US clinical trials, 1 recruiting.
Enanta Pharmaceuticals sponsors 36 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 32 completed. 0 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is RSV Infection, with 3 trials.
Top-decile sponsor footprint
Enanta Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 35 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
36 total, page 1 of 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT07540910
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
NCT06917508
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
NCT06847464
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
NCT06601192
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
NCT05568706
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
NCT05616728
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
NCT05594602
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
NCT05594615
A Study of EDP-323 in Healthy Subjects
NCT05587478
A Study to Evaluate EDP 938 Regimens in Children With RSV
NCT04816721
A Study of EDP-235 in Healthy Subjects
NCT05246878
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
NCT04633187
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
NCT04927793
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
NCT04871724
Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects
NCT04783753
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
NCT04498741
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
NCT04378010
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
NCT04196101
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
NCT04008004
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
NCT03755778
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
NCT03783897
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
NCT03750383
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
NCT03748628
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
NCT03610945
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
NCT03421431
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
NCT03394924
A Study of EDP-938 in Healthy Subjects
NCT03384823
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
NCT03213145
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
NCT03207425
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
NCT03187496
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
NCT02918929
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788
NCT02255968
Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788
NCT01999725
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
NCT01856426
Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers
NCT00990145
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
NCT00989872
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 8 |
What is open in the Enanta Pharmaceuticals pipeline
1 recruiting of 36 indexed (3% open); 32 completed (89%).
Phase mix: 0 late (III/IV) vs 36 early (I/II) (early-phase heavy).
Top condition: RSV Infection (3 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Enanta Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 36 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Enanta Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 36 trials (± recruiting share)
- Acorda Therapeutics · 36 trials · 0% recruiting
- Baystate Medical Center · 36 trials · 17% recruiting
- Eastern Virginia Medical School · 36 trials · 17% recruiting
- MacroGenics · 36 trials · 11% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
- Appalachian State University · 3% recruiting · 37 trials
- Bracco Diagnostics · 3% recruiting · 37 trials
- Janssen Scientific Affairs · 3% recruiting · 37 trials
Related
What to do with this Enanta Pharmaceuticals page
36 registered trials is a research-attention snapshot, not an endorsement of Enanta Pharmaceuticals or any single study.
- 1 of Enanta Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- RSV Infection is the condition Enanta Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See RSV Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Enanta Pharmaceuticals pipeline card: 36 registered trials from official public datasets.Report a data error.